Loading clinical trials...
Loading clinical trials...
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
Conditions
Interventions
BCA101
Pembrolizumab
Locations
20
United States
Moores Cancer Center UC San Diego Health
La Jolla, California, United States
Keck School of Medicine of USC
Los Angeles, California, United States
UCLA
Los Angeles, California, United States
University of California, Davis Comprehensive Cancer Center
Sacramento, California, United States
H. Lee Moffitt Cancer Center and Research Institute, Inc
Tampa, Florida, United States
Dana Farber/Partners Cancer Care Inc
Boston, Massachusetts, United States
Start Date
June 1, 2020
Primary Completion Date
December 31, 2026
Completion Date
June 1, 2027
Last Updated
August 15, 2025
NCT07446322
NCT06532279
NCT07541924
NCT07536113
NCT04693377
NCT07529301
Lead Sponsor
Bicara Therapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions